Cargando…

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study

BACKGROUND: Limited data are available on applying circulating tumor DNA (ctDNA) in metastatic triple-negative breast cancer (mTNBC) patients. Here, we investigated the value of ctDNA for predicting the prognosis and monitoring the treatment response in mTNBC patients. METHODS: We prospectively enro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Yajing, Su, Mu, Zhou, Dongdong, Zheng, Fangchao, Zhang, Baoxuan, Qiang, Ling, Ren, Guohua, Song, Lihua, Bu, Bing, Fang, Shu, Yu, Bo, Zhou, Jinxing, Yu, Jinming, Li, Huihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627511/ https://www.ncbi.nlm.nih.gov/pubmed/37929934 http://dx.doi.org/10.7554/eLife.90198

Ejemplares similares

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer
por: Tan, Qiaorui, et al.
Publicado: (2023)

A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population
por: Li, Huihui, et al.
Publicado: (2017)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature
por: Lisencu, Lorena Alexandra, et al.
Publicado: (2022)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

T-cadherin is associated with prognosis in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2017)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
por: Jin, Jia, et al.
Publicado: (2018)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

Survival analysis and nomogram for early-stage occult breast cancer with positive lymph nodes based on the SEER database
por: Man, Xiaochu, et al.
Publicado: (2022)

Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer
por: Shang, Mao, et al.
Publicado: (2018)

An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer
por: Tierno, Domenico, et al.
Publicado: (2023)

Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
por: Pu, Shengyu, et al.
Publicado: (2022)

Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins
por: Zhou, Yu-Dong, et al.
Publicado: (2018)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages
por: Sun, Shujuan, et al.
Publicado: (2023)

A nomogram prediction for the survival of patients with triple negative breast cancer
por: Lin, Yuxiang, et al.
Publicado: (2018)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Huang, Yunxia, et al.
Publicado: (2023)

VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
por: Cao, Xi, et al.
Publicado: (2021)

Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy
por: Ma, Jianli, et al.
Publicado: (2023)

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
por: Chi, Yajing, et al.
Publicado: (2022)

Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China
por: Zhang, Yanwu, et al.
Publicado: (2017)

Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer
por: Zeng, Zhihao, et al.
Publicado: (2017)

Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer
por: Zhou, Qin, et al.
Publicado: (2023)

Aurora-A Identifies Early Recurrence and Poor Prognosis and Promises a Potential Therapeutic Target in Triple Negative Breast Cancer
por: Xu, Jie, et al.
Publicado: (2013)

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
por: Fernandez, Sandra V, et al.
Publicado: (2014)

The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer
por: Wu, Sijia, et al.
Publicado: (2021)

Clinical features and prognosis of triple-negative breast cancer
por: Sanz, M Izquierdo, et al.
Publicado: (2009)

Mutational characteristics determined using circulating tumor DNA analysis in triple‐negative breast cancer patients with distant metastasis
por: Rong, Guohua, et al.
Publicado: (2020)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
por: Meng, Xiangdi, et al.
Publicado: (2023)

No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment
por: Mu, Lan, et al.
Publicado: (2017)

Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer
por: Wang, Shanshan, et al.
Publicado: (2021)

Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer
por: Zheng, Chao, et al.
Publicado: (2022)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
por: Liu, Minetta C, et al.
Publicado: (2019)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_74ge4dig7epfa5lkln81tvn252